EP 4192495 A1 20230614 - FGF21 COMBINED WITH CCR2/5 ANTAGONISTS FOR THE TREATMENT OF FIBROSIS
Title (en)
FGF21 COMBINED WITH CCR2/5 ANTAGONISTS FOR THE TREATMENT OF FIBROSIS
Title (de)
FGF21 IN KOMBINATION MIT CCR2/5-ANTAGONISTEN ZUR BEHANDLUNG VON FIBROSE
Title (fr)
FGF21 COMBINÉ À DES ANTAGONISTES DE CCR2/5 POUR LE TRAITEMENT DE LA FIBROSE
Publication
Application
Priority
- US 202063063189 P 20200807
- US 202063065414 P 20200813
- US 202063065749 P 20200814
- US 202063065935 P 20200814
- US 202063067184 P 20200818
- US 2021045090 W 20210806
Abstract (en)
[origin: WO2022032187A1] The present application provides methods of treating a fibrosis and/or diabetes comprising administering a FGF-21 polypeptide in combination with a CCR2/5 dual antagonist. The method can also be used to treat NASH.
IPC 8 full level
A61K 38/18 (2006.01); A61K 31/4178 (2006.01); A61K 31/53 (2006.01); A61K 47/60 (2017.01); A61P 1/16 (2006.01)
CPC (source: EP)
A61K 31/517 (2013.01); A61K 31/53 (2013.01); A61K 38/1825 (2013.01); A61K 47/60 (2017.08); A61P 1/16 (2018.01)
C-Set (source: EP)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2022032187 A1 20220210; EP 4192495 A1 20230614; JP 2023538533 A 20230908
DOCDB simple family (application)
US 2021045090 W 20210806; EP 21773170 A 20210806; JP 2023509393 A 20210806